Subjects of human abuse potential (HAP) studies must be able to detect liking with the investigational drug. However, many subjects recruited for HAP studies use marijuana, and THC is often exempt from exclusion by urine drug tests (UDTs). PRA Health Sciences examined whether UDT evidence of recent marijuana use was associated with a difference in subjects’ ability to discriminate opioid from placebo. Successful opioid discriminators were associated with a statistically insignificant, but higher positive THC UDT rate and mean carboxy-THC urine concentration when compared to non-discriminators, indicating that recent users of marijuana may not need to be excluded from opioid HAP studies.
Explore related content and topics

Predicting Screen Failure Rates of Human Abuse Potential Studies
Human Abuse Potential (HAP) studies are required for New Drug Approvals of all drugs that have a potential psychoactive effect. The steps of…

Ewoud-Jan van Hoogdalem, Vice President of Scientific Affairs, Clinical Pharmacology
We measure our HQ with actions, experiences, and intentions. Nowhere is that more evident that in the stories of our subject matter experts. We want…

Oral Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone
Hydrocodone bitartrate (HB) and acetaminophen (APAP) combination products are known to be abused via oral, intranasal, and intravenous…